Esperion Therapeutics, Inc.

NasdaqGM:ESPR Stock Report

Market Cap: US$444.8m

Esperion Therapeutics Future Growth

Future criteria checks 5/6

Esperion Therapeutics is forecast to grow earnings and revenue by 58.9% and 38.3% per annum respectively while EPS is expected to grow by 61.1% per annum.

Key information

58.9%

Earnings growth rate

61.1%

EPS growth rate

Pharmaceuticals earnings growth20.9%
Revenue growth rate38.3%
Future return on equityn/a
Analyst coverage

Good

Last updated06 Feb 2024

Recent future growth updates

Recent updates

Navigating Esperion Therapeutics' Surprise Secondary Offering: Some Investment Considerations

Jan 22

Esperion Is Sitting On A Potential Blockbuster Drug

Jan 14

Many Still Looking Away From Esperion Therapeutics, Inc. (NASDAQ:ESPR)

Jun 19
Many Still Looking Away From Esperion Therapeutics, Inc. (NASDAQ:ESPR)

Upgrade: Analysts Just Made A Substantial Increase To Their Esperion Therapeutics, Inc. (NASDAQ:ESPR) Forecasts

Mar 09
Upgrade: Analysts Just Made A Substantial Increase To Their Esperion Therapeutics, Inc. (NASDAQ:ESPR) Forecasts

Analysts Have Just Cut Their Esperion Therapeutics, Inc. (NASDAQ:ESPR) Revenue Estimates By 18%

Feb 23
Analysts Have Just Cut Their Esperion Therapeutics, Inc. (NASDAQ:ESPR) Revenue Estimates By 18%

Esperion says Nexletol recommended as oral non-statin therapy for lowering cholesterol

Aug 26

Esperion Therapeutics: Positive Update On CLEAR Outcomes Trial Offsets Mixed Q2 Earnings

Aug 09

Esperion Therapeutics Q2 2022 Earnings Preview

Aug 01

Esperion Therapeutics: 2021 Labors Paying Off In 2022

May 07

Esperion Therapeutics: Ready For Growth Ahead Of Clear Outcomes Topline Data Readout

Feb 24

Esperion Therapeutics: A Potential 'Bio Boom' Or Bust In 2022

Jan 20

Esperion: Bullish On Cost-Cutting Ahead Of Expected Demand Inflection

Oct 27

Esperion: Hunting Big Game In The Danger Zone

Aug 05

Esperion Therapeutics, Inc. (NASDAQ:ESPR) Analysts Are Reducing Their Forecasts For This Year

May 09
Esperion Therapeutics, Inc. (NASDAQ:ESPR) Analysts Are Reducing Their Forecasts For This Year

Esperion Therapeutics, Inc. 2021 Q1 - Results - Earnings Call Presentation

May 04

Esperion Therapeutics: Deeply Undervalued With An Extremely High Short Interest

Jan 30

Esperion Therapeutics (ESPR) Presents At 39th Annual Healthcare Conference - Slideshow

Jan 14

Bullish: Analysts Just Made A Significant Upgrade To Their Esperion Therapeutics, Inc. (NASDAQ:ESPR) Forecasts

Jan 14
Bullish: Analysts Just Made A Significant Upgrade To Their Esperion Therapeutics, Inc. (NASDAQ:ESPR) Forecasts

Esperion announces deal with Serometrix and gives out Q4 U.S. products revenue forecast

Jan 13

Need To Know: Esperion Therapeutics, Inc. (NASDAQ:ESPR) Insiders Have Been Buying Shares

Dec 26
Need To Know: Esperion Therapeutics, Inc. (NASDAQ:ESPR) Insiders Have Been Buying Shares

Earnings and Revenue Growth Forecasts

NasdaqGM:ESPR - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/2026702313N/AN/A2
12/31/202543780N/AN/A4
12/31/2024305-36146858
12/31/2023113-209-65-1248
9/30/2023103-208-141-141N/A
6/30/202388-222-164-164N/A
3/31/202381-239-190-190N/A
12/31/202275-234-175-175N/A
9/30/202272-243-190-190N/A
6/30/202267-258-216-216N/A
3/31/202289-235-214-214N/A
12/31/202178-269-264-264N/A
9/30/202173-308-287-275N/A
6/30/202162-325-305-292N/A
3/31/2021234-156-118-105N/A
12/31/2020228-144-99-85N/A
9/30/2020219-101-67-67N/A
6/30/2020216-84-39-38N/A
3/31/20205-263-232-231N/A
12/31/2019148-97-71-70N/A
9/30/2019147-95-50-49N/A
6/30/2019146-77-29-29N/A
3/31/2019145-68-14-14N/A
12/31/2018N/A-202-149-149N/A
9/30/2018N/A-180-155-155N/A
6/30/2018N/A-175-153-153N/A
3/31/2018N/A-173-140-140N/A
12/31/2017N/A-167-131-131N/A
9/30/2017N/A-158-113-113N/A
6/30/2017N/A-130N/A-91N/A
3/31/2017N/A-101N/A-72N/A
12/31/2016N/A-75N/A-48N/A
9/30/2016N/A-59N/A-40N/A
6/30/2016N/A-55N/A-37N/A
3/31/2016N/A-53N/A-39N/A
12/31/2015N/A-50N/A-38N/A
9/30/2015N/A-46N/A-38N/A
6/30/2015N/A-43N/A-35N/A
3/31/2015N/A-40N/A-32N/A
12/31/2014N/A-36N/A-32N/A
9/30/2014N/A-37N/A-31N/A
6/30/2014N/A-32N/A-27N/A
3/31/2014N/A-30N/A-25N/A
12/31/2013N/A-26N/A-18N/A
9/30/2013N/A-19N/A-13N/A
6/30/2013N/A-17N/A-11N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: ESPR is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.3%).

Earnings vs Market: ESPR is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: ESPR is expected to become profitable in the next 3 years.

Revenue vs Market: ESPR's revenue (38.3% per year) is forecast to grow faster than the US market (8% per year).

High Growth Revenue: ESPR's revenue (38.3% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if ESPR's Return on Equity is forecast to be high in 3 years time


Discover growth companies

Price7D1Y
Mkt CapP/EGrowth
Price7D1Y
Mkt CapP/EGrowth
Price7D1Y
Mkt CapP/EGrowth
Price7D1Y
Mkt CapP/EGrowth
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.